Lo T, Lent-Schochet D, Luu KY, et al. - Researchers conducted this retrospective study to identify factors associated with successful treatment discontinuation in eyes with retinal vein occlusions (RVOs) and macular edema (ME) in real-world settings. They analyzed 214 eyes with RVO and ME with a 24-month follow-up at five academic centers. Data reported that 40% of eyes with branch RVO and 35% with central RVO (CRVO) / hemi-retinal RVO (HRVO) successfully stopped therapy without fluid recurrence, with a median time to discontinuation of 6 and 7 months, respectively. Lower 6-month central subfield thickness was correlated with a greater likelihood of treatment discontinuation within 24 months for eyes with CRVO/HRVO, while better 6-month BCVA was related to better 24-month BCVA for all RVO subtypes. Overall, the authors concluded that early anatomic response at 6 months is linked to a greater likelihood of discontinuing treatments.